BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

655 related articles for article (PubMed ID: 34616392)

  • 1. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
    Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
    Front Immunol; 2021; 12():686439. PubMed ID: 34616392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice.
    Bézie S; Charreau B; Vimond N; Lasselin J; Gérard N; Nerrière-Daguin V; Bellier-Waast F; Duteille F; Anegon I; Guillonneau C
    Blood Adv; 2019 Nov; 3(22):3522-3538. PubMed ID: 31730699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells.
    Dawson NA; Lamarche C; Hoeppli RE; Bergqvist P; Fung VC; McIver E; Huang Q; Gillies J; Speck M; Orban PC; Bush JW; Mojibian M; Levings MK
    JCI Insight; 2019 Mar; 4(6):. PubMed ID: 30753169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
    Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
    Front Immunol; 2018; 9():2359. PubMed ID: 30369931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection.
    Boardman DA; Philippeos C; Fruhwirth GO; Ibrahim MA; Hannen RF; Cooper D; Marelli-Berg FM; Watt FM; Lechler RI; Maher J; Smyth LA; Lombardi G
    Am J Transplant; 2017 Apr; 17(4):931-943. PubMed ID: 28027623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced dysfunction.
    Lamarthée B; Marchal A; Charbonnier S; Blein T; Leon J; Martin E; Rabaux L; Vogt K; Titeux M; Delville M; Vinçon H; Six E; Pallet N; Michonneau D; Anglicheau D; Legendre C; Taupin JL; Nemazanyy I; Sawitzki B; Latour S; Cavazzana M; André I; Zuber J
    Nat Commun; 2021 Nov; 12(1):6446. PubMed ID: 34750385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
    Boroughs AC; Larson RC; Choi BD; Bouffard AA; Riley LS; Schiferle E; Kulkarni AS; Cetrulo CL; Ting D; Blazar BR; Demehri S; Maus MV
    JCI Insight; 2019 Mar; 5(8):. PubMed ID: 30869654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor.
    MacDonald KG; Hoeppli RE; Huang Q; Gillies J; Luciani DS; Orban PC; Broady R; Levings MK
    J Clin Invest; 2016 Apr; 126(4):1413-24. PubMed ID: 26999600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival.
    Wagner JC; Ronin E; Ho P; Peng Y; Tang Q
    Am J Transplant; 2022 Sep; 22(9):2237-2245. PubMed ID: 35434896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation.
    Gille I; Claas FHJ; Haasnoot GW; Heemskerk MHM; Heidt S
    Front Immunol; 2022; 13():874157. PubMed ID: 35720402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor.
    Noyan F; Zimmermann K; Hardtke-Wolenski M; Knoefel A; Schulde E; Geffers R; Hust M; Huehn J; Galla M; Morgan M; Jokuszies A; Manns MP; Jaeckel E
    Am J Transplant; 2017 Apr; 17(4):917-930. PubMed ID: 27997080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4
    Fu RY; Chen AC; Lyle MJ; Chen CY; Liu CL; Miao CH
    Cell Immunol; 2020 Dec; 358():104216. PubMed ID: 32987195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Building a CAR-Treg: Going from the basic to the luxury model.
    Rosado-Sánchez I; Levings MK
    Cell Immunol; 2020 Dec; 358():104220. PubMed ID: 33096321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do Treg Speed Up with CARs? Chimeric Antigen Receptor Treg Engineered to Induce Transplant Tolerance.
    Kaljanac M; Abken H
    Transplantation; 2023 Jan; 107(1):74-85. PubMed ID: 36226849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
    Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes.
    Tenspolde M; Zimmermann K; Weber LC; Hapke M; Lieber M; Dywicki J; Frenzel A; Hust M; Galla M; Buitrago-Molina LE; Manns MP; Jaeckel E; Hardtke-Wolenski M
    J Autoimmun; 2019 Sep; 103():102289. PubMed ID: 31176558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression.
    De Paula Pohl A; Schmidt A; Zhang AH; Maldonado T; Königs C; Scott DW
    Cell Immunol; 2020 Dec; 358():104222. PubMed ID: 33053469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.